Annual EBITDA
-$109.63 M
+$118.17 M+51.88%
December 31, 2024
Summary
- As of March 2, 2025, ARQT annual EBITDA is -$109.63 million, with the most recent change of +$118.17 million (+51.88%) on December 31, 2024.
- During the last 3 years, ARQT annual EBITDA has risen by +$96.28 million (+46.76%).
- ARQT annual EBITDA is now -2569.87% below its all-time high of -$4.11 million, reached on December 31, 2017.
Performance
ARQT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$4.46 M
+$29.00 M+86.68%
December 31, 2024
Summary
- As of March 2, 2025, ARQT quarterly EBITDA is -$4.46 million, with the most recent change of +$29.00 million (+86.68%) on December 31, 2024.
- Over the past year, ARQT quarterly EBITDA has increased by +$53.66 million (+92.33%).
- ARQT quarterly EBITDA is now at all-time high.
Performance
ARQT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$109.63 M
+$53.66 M+32.86%
December 31, 2024
Summary
- As of March 2, 2025, ARQT TTM EBITDA is -$109.63 million, with the most recent change of +$53.66 million (+32.86%) on December 31, 2024.
- Over the past year, ARQT TTM EBITDA has increased by +$118.23 million (+51.89%).
- ARQT TTM EBITDA is now -1741.51% below its all-time high of -$5.95 million, reached on December 31, 2018.
Performance
ARQT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ARQT EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +51.9% | +92.3% | +51.9% |
| 3 y3 years | +46.8% | +86.8% | +53.3% |
| 5 y5 years | -154.6% | +86.8% | +53.3% |
ARQT EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +62.8% | at high | +95.7% | at high | +64.1% |
| 5 y | 5-year | -154.6% | +62.8% | at high | +95.7% | -154.6% | +64.1% |
| alltime | all time | -2569.9% | +62.8% | at high | +95.7% | -1741.5% | +64.1% |
Arcutis Biotherapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$109.63 M(-51.9%) | -$4.46 M(-86.7%) | -$109.63 M(-32.9%) |
| Sep 2024 | - | -$33.45 M(-24.8%) | -$163.28 M(-0.2%) |
| Jun 2024 | - | -$44.50 M(+63.5%) | -$163.63 M(-10.3%) |
| Mar 2024 | - | -$27.22 M(-53.2%) | -$182.38 M(-20.0%) |
| Dec 2023 | -$227.79 M(-22.7%) | -$58.11 M(+71.9%) | -$227.86 M(-2.8%) |
| Sep 2023 | - | -$33.80 M(-46.6%) | -$234.50 M(-22.7%) |
| Jun 2023 | - | -$63.26 M(-13.0%) | -$303.24 M(-0.7%) |
| Mar 2023 | - | -$72.69 M(+12.3%) | -$305.23 M(+3.5%) |
| Dec 2022 | -$294.87 M(+43.2%) | -$64.76 M(-36.8%) | -$294.87 M(-2.1%) |
| Sep 2022 | - | -$102.53 M(+57.1%) | -$301.31 M(+17.9%) |
| Jun 2022 | - | -$65.25 M(+4.7%) | -$255.64 M(+10.1%) |
| Mar 2022 | - | -$62.34 M(-12.4%) | -$232.29 M(+12.8%) |
| Dec 2021 | -$205.90 M | -$71.19 M(+25.2%) | -$205.90 M(+22.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$56.86 M(+35.7%) | -$167.77 M(+12.5%) |
| Jun 2021 | - | -$41.90 M(+16.6%) | -$149.18 M(+4.4%) |
| Mar 2021 | - | -$35.94 M(+8.7%) | -$142.88 M(+5.4%) |
| Dec 2020 | -$135.56 M(+214.8%) | -$33.06 M(-13.6%) | -$135.56 M(+17.4%) |
| Sep 2020 | - | -$38.27 M(+7.5%) | -$115.46 M(+25.8%) |
| Jun 2020 | - | -$35.60 M(+24.4%) | -$91.82 M(+41.8%) |
| Mar 2020 | - | -$28.62 M(+120.7%) | -$64.76 M(+50.4%) |
| Dec 2019 | -$43.06 M(+118.2%) | -$12.97 M(-11.3%) | -$43.06 M(+19.5%) |
| Sep 2019 | - | -$14.63 M(+71.4%) | -$36.05 M(+68.3%) |
| Jun 2019 | - | -$8.54 M(+23.2%) | -$21.42 M(+66.3%) |
| Mar 2019 | - | -$6.93 M(+16.4%) | -$12.88 M(+116.4%) |
| Dec 2018 | -$19.73 M(+380.6%) | -$5.95 M | -$5.95 M |
| Dec 2017 | -$4.11 M | - | - |
FAQ
- What is Arcutis Biotherapeutics annual EBITDA?
- What is the all time high annual EBITDA for Arcutis Biotherapeutics?
- What is Arcutis Biotherapeutics annual EBITDA year-on-year change?
- What is Arcutis Biotherapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Arcutis Biotherapeutics?
- What is Arcutis Biotherapeutics quarterly EBITDA year-on-year change?
- What is Arcutis Biotherapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Arcutis Biotherapeutics?
- What is Arcutis Biotherapeutics TTM EBITDA year-on-year change?
What is Arcutis Biotherapeutics annual EBITDA?
The current annual EBITDA of ARQT is -$109.63 M
What is the all time high annual EBITDA for Arcutis Biotherapeutics?
Arcutis Biotherapeutics all-time high annual EBITDA is -$4.11 M
What is Arcutis Biotherapeutics annual EBITDA year-on-year change?
Over the past year, ARQT annual EBITDA has changed by +$118.17 M (+51.88%)
What is Arcutis Biotherapeutics quarterly EBITDA?
The current quarterly EBITDA of ARQT is -$4.46 M
What is the all time high quarterly EBITDA for Arcutis Biotherapeutics?
Arcutis Biotherapeutics all-time high quarterly EBITDA is -$4.46 M
What is Arcutis Biotherapeutics quarterly EBITDA year-on-year change?
Over the past year, ARQT quarterly EBITDA has changed by +$53.66 M (+92.33%)
What is Arcutis Biotherapeutics TTM EBITDA?
The current TTM EBITDA of ARQT is -$109.63 M
What is the all time high TTM EBITDA for Arcutis Biotherapeutics?
Arcutis Biotherapeutics all-time high TTM EBITDA is -$5.95 M
What is Arcutis Biotherapeutics TTM EBITDA year-on-year change?
Over the past year, ARQT TTM EBITDA has changed by +$118.23 M (+51.89%)